Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
DMAC Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: May 26, 2026
Report Source: 2026 1st Quarter Report
DiaMedica Therapeutics Inc. Stock Analysis DMAC
United States Health Care Small Cap Report: DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. The company is headquartered in Minneapolis, Minnesota and currently employs 35 full-time employees. The company went IPO on 2008-01-04. The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
Read More DiaMedica Therapeutics Inc (DMAC) Chart
Key Statistics of DiaMedica Therapeutics Inc (DMAC)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$5.78Volume
216.71KP/E Ratio (TTM)
-52 Week Range
Market Cap
310.91MAvg. Volume
174.02KDividend Yield
-Financial Metrics & Statements of DiaMedica Therapeutics Inc (DMAC)
FAQ's for DiaMedica Therapeutics Inc (DMAC)
- According to Musaffa’s Shariah screening methodology, DiaMedica Therapeutics Inc (DMAC) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes DiaMedica Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in DiaMedica Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of DiaMedica Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of DiaMedica Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of DiaMedica Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.